Elicitation of health state utilities in soft tissue sarcoma

Quality of Life Research

Volumn 22, Issue 7, 2013, Pages 1697-1706

  Shingler, Sarah L ^a   Swinburn, Paul ^a   Lloyd, Andrew ^a   Diaz, Jose ^b   Isbell, Robert ^b   Manson, Stephanie ^b   Benson, Charlotte ^c  

^a ICON PLC   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Economic evaluation; Health related quality of life; Soft tissue sarcoma

Indexed keywords

ADULT; ARTICLE; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; ECONOMICS; FEMALE; HEALTH CARE COST; HEALTH STATUS; HUMAN; INTERVIEW; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PSYCHOLOGICAL ASPECT; QUALITATIVE RESEARCH; QUALITY OF LIFE; QUESTIONNAIRE; SARCOMA; SICKNESS IMPACT PROFILE; SOCIOECONOMICS; TREATMENT OUTCOME; PSYCHOLOGY;

ADULT; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HEALTH CARE COSTS; HEALTH STATUS; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; NEOPLASM METASTASIS; QUALITATIVE RESEARCH; QUALITY OF LIFE; QUESTIONNAIRES; SARCOMA; SICKNESS IMPACT PROFILE; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 84884417040     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-012-0301-9     Document Type: Article

References (26)

1. Carter, N. J.; & Keam, S. J. (2010). Trabectedin a review of its use in soft tissue sarcoma and ovarian cancer. Drugs, 70(3), 355-376.
2. Vincenzi, B.; Frezza, A. M.; Santani, D.; et al. (2010). New therapies in soft tissue sarcoma. Expert Opinion, 15(2), 237-248.
3. Casali, P. G.; Jost, L.; Sleijfer, S.; et al. (2008). Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 19(Supp 2), 89-93.
4. Hensley, M. L. (2010). Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas. Current Opinion in Oncology, 22, 356-361.
5. National Cancer Institute, Surveillance Epidemiology and End Results (NCI SEER), 2008. Available from: http://seer.cancer.gov/statfacts/html/soft.html Accessed on 10 December 2011.
6. Parsons, J. A.; & Davis, A. M. (2004). Rehabilitation and quality-of-life issues in patients with extremity soft tissue sarcoma. Current Treatment Options in Oncology, 5, 477-488.
7. Peiper M.; Matthaei H.; Bölke E.; Zurakowski D.; Orth K.; Heinecke A.; et al.(2011) Compartmental resection for subfascial extremity soft tissue sarcoma and quality of life in long-term survivors. Wien Klin Wochenschr doi: 10.1007/s00508-011-1592-5.
8. Brooks, R. (1996). EuroQol: The current state of play. Health Policy, 37(1), 53-72.
9. National Institute of Health and Clinical Excellence (NICE). (2008). Guide to the methods of technology appraisal. London: NICE.
10. Kontodimopoulos, N.; Aletras, V. H.; Paliouras, D.; et al. (2009). Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value Health, 12, 1151-1157.
11. Crott R.; Briggs A. (2010) Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Eur J Health Econ;11(4):427-34. Epub 2010 May 16.
12. Petrill, J.; & Cairns, J. (2008). Converting condition-specific measures into preference-based outcomes for use in economic evaluation. Expert Review on Pharmacoecon Outcomes Research, 8(5), 453-461.
13. Torrance, G. W. (1986). Measurement of health state utilities for economic appraisal. Journal of Health Economics, 5, 1-30.
14. Office of National Statistics (ONS), Website: (2001) Population of the United Kingdom: by ethnic group: http://www.ons.gov.uk/ons/index.html. Accessed on 09 December 2011.
15. Lloyd, A.; Nafees, B.; Narewska, D. S.; & Watkins, J. (2006). Health state utilities for metastatic breast cancer. British Journal of Cancer, 95, 683-690.
16. Nafees, B.; Stafford, M.; Gavriel, S.; Bhalla, S.; & Watkins, J. (2008). Health state utilities for non-small cell lung cancer. Health and Quality of Life Outcomes, 6, 84.
17. Kind, P.; Dolan, P.; Gudex, C.; & Williams, A. (1998). Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ, 316, 736.
18. Launois, R.; Reboul-Marty, J. M.; Henry, B.; & Bonneterre, J. (1997). A cost/utility analysis of second line chemotherapy in metastatic breast cancer. Pharmaco Economics, 11(5), 495-497.
19. Kattan, M. W.; Cowen, M. E.; & Miles, B. J. (1997). A decision analysis for treatment of clinically localized prostate cancer. Journal of General Internal Medicine, 12(5), 299-305.
20. Swinburn, P.; Lloyd, A.; Nathan, P.; Choueiri, T. K.; Cella, D.; & Neary, M. (2010). Elicitation of health state utilities in metastatic renal cell carcinoma. Current Medical Research and Opinion, 26(5), 1091-1096.
21. Coghill D.; et al. (2004) Measuring quality of life in children with attention-deficit-hyperactivity disorder in the United Kingdom. 16th World Congress of the International Association of Child and Adolescent Psychiatry and Allied Professions (IACAPAP).
22. Lloyd A. (2011). Estimation of Utilities in Attention-Deficit Hyperactivity Disorder for Economic Evaluations Patient; 4 (4): 247-257.
23. Ubel, P. A.; Loewenstein, G.; & Jepson, C. (2003). Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Quality of Life Research, 12, 599-607.
24. Kostopoulou, O. (2006). The transient nature of utilities and health preferences. Medical Decision Making, 26, 304-306.
25. Dolan, P.; & Kahneman, D. (2008). Interpretations of utility and their implications for the valuation of health. The Economic Journal, 18, 215-234.
26. Blumenschein K.; Blomquist G.; Johannesson M. et al. Eliciting willingness to pay without bias: Evidence from a field experiment. The Economic Journal; 18: 114-137.